Why Vir Biotechnology Stock Is Skyrocketing Today
Shares of Vir Biotechnology (NASDAQ: VIR) are soaring through the roof on Wednesday following the company's announcement of the start of a clinical trial to evaluate one of its pipeline candidates as part of a potential combination therapy for COVID-19. As of 1:29 p.m. EST, shares of the biotech are up by 32.5%, after rising by as much as 79% earlier today. Vir Biotechnology is developing VIR-7831 in collaboration with GlaxoSmithKline (NYSE: GSK).
